GlassScriptPhysician profile
Victoria Boldman
NPI 1356852081
$1,052.70
in general payments reported to CMS, 2019-2025
15 companies · $146 in 2025
The $146 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.58 · 2022: $201 · 2023: $382 · 2024: $309 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $836.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $229.91 | 2023-2025 | Qutenza |
| Curonix LLC | $190.60 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.91 | 2023-2025 | Xifaxan |
| Novo Nordisk INC | $105.57 | 2023-2024 | Rybelsus, Ozempic |
| Teva Pharmaceuticals USA, INC. | $62.01 | 2022 | |
| Janssen Pharmaceuticals, INC | $61.19 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $47.34 | 2022 | |
| Abbott Laboratories | $39.91 | 2023-2025 | Proclaim, Eterna |
| Relievant Medsystems, INC. | $38.70 | 2023 | Intracept |
| Indivior INC. | $29.70 | 2022 | |
| Medtronic, INC. | $20.39 | 2025 | Inceptiv |
| Glaxosmithkline, LLC. | $19.13 | 2025 | Trelegy Ellipta |
| Mml US, INC. | $18.09 | 2025 | Reactiv8 |
| Alkermes, INC. | $15.78 | 2022 | |
| Amgen INC. | $14.47 | 2023 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Boldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.